Nycomed is building up its dermatology operations with its deal to buy Bradley Pharmaceuticals. Executives involved in the merger say that the acquisition--at $20 a share--will position Nycomed to in-license and co-promote dermatology products. Paul McGarty, CEO of Nycomed US added: "This brings together the strengths of both companies with the objective of creating a leading specialty pharmaceutical player in dermatology." Release